Through collaborative efforts with multiple industry partners, Celerus
Diagnostics has successfully demonstrated Rapid ISH™ (in-situ
hybridization) on its forthcoming Wave RPD System. In-situ hybridization
uses a labeled complementary DNA or RNA strand to localize a specific
sequence in a section of tissue. This is distinct from
immunohistochemistry which localizes proteins in tissue sections.
“This is significant
because the importance of molecular targets as companion diagnostics to
identify patients for drug therapies continues to grow.”
“The combination of on-board heating and our proprietary Wave
technology has dramatically improved hybridization efficiencies for
ISH assays,” said Marc Key, Chief Scientific Officer.
“We've had success with both fluorescent and chromogenic markers,” said
Jason Lusk, Vice President of Business Development. “This is significant
because the importance of molecular targets as companion diagnostics to
identify patients for drug therapies continues to grow.”
Celerus Diagnostics will launch the Wave RPD System, a totally automated
immunohistochemistry (IHC) and in-situ-hybridization (ISH) staining
system to the market this year. The new system will be introduced at the
United States and Canadian Association of Pathologists annual meeting
being held in Washington DC, March 22–24.
“We continue to expand the capabilities of our core rapid incubation
technology by adding on-board heating and subsequently applying it to a
broadening array of protein and molecular assays,” CEO Dave Gross added.
In 2008 Celerus Diagnostics introduced Rapid IHC® with its Wave
System, a semi-automated platform that delivers high-quality IHC
results in 15 minutes. The addition of on-board pretreatment steps to
the existing 15-minute staining protocols, results in totally automated
IHC in one hour, compared to industry standards of two-and-a-half to
four hours.